Vaccine News and Research

Latest Vaccine News and Research

Synexus' Chief Medical Officer to discuss vaccine trial challenges at Washington event

Dr Glynis Neagle, Synexus' Chief Medical Officer will be discussing the challenges facing global vaccine trials at the World Vaccine Congress in Washington this week.

From AES - Accelerated Enrollment Solutions 11 Apr 2011

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that Pfizer has agreed to support its pivotal Phase III trial with IMA901, its therapeutic cancer vaccine for advanced renal cell carcinoma.

11 Apr 2011

Immunization does not increase emergency room visit in children with inherited disorders

Children with inborn errors of metabolism received vaccines on the same immunization schedule as did healthy infants, according to Kaiser Permanente Vaccine Study Center scientists who examined the Kaiser Permanente Northern California population. In addition, immunization was not associated with significant increases in emergency room visits or hospitalizations during the month following vaccination, according to Nicola Klein, MD, PhD, lead author of the study and co-director of the Kaiser Permanente Vaccine Study Center.

11 Apr 2011

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Merck, known as MSD outside the United States and Canada, and Intercell AG today announced that following a pre-specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus infection, the independent Data Monitoring Committee recommended suspension of enrollment.

11 Apr 2011

Gilenya can reduce risk of disability progression in patients with RRMS

A new analysis demonstrated that Gilenya reduced the risk of disability progression in patients with relapsing-remitting multiple sclerosis, regardless of treatment history. This analysis of the phase III two-year FREEDOMS study is one of 11 abstracts on Gilenya being presented at the 63rd annual meeting of the American Academy of Neurology.

11 Apr 2011

IDSA, U.S. health officials describe ways to respond to global threat of antimicrobial resistance

To coincide with World Health Day on Thursday, the Infectious Diseases Society of America (IDSA) released a policy paper with nine recommendations for how to control the "ever-growing threat of antimicrobial resistance," CIDRAP News reports.

11 Apr 2011

Scientists identify novel mechanism to control cancer spread

Saint Louis University researchers have identified a novel mechanism to control the traffic of cells and fluid from tissues to lymphatic vessels. It may be possible to harness this mechanism to fight cancer spread from one organ to another organ and improve the effectiveness of vaccines.

11 Apr 2011

New dengue test receives FDA marketing clearance

The U.S. Food and Drug Administration today allowed marketing of the first test to help diagnose people with signs and symptoms of dengue fever or dengue hemorrhagic fever, a leading cause of illness and death in the tropics and subtropics.

11 Apr 2011

Key regulator of fat cell development may provide a target for obesity and diabetes drugs

New research by scientists at The Scripps Research Institute and collaborating institutions has identified a key regulator of fat cell development that may provide a target for obesity and diabetes drugs.

8 Apr 2011

GeoVax Labs to update its HIV/AIDS vaccine status at World Vaccine Conference

Harriet Robinson, Ph.D., Chief Scientific Officer at GeoVax Labs, Inc., will provide an update on the status of the Company's therapeutic and preventative HIV vaccines at the 2011 World Vaccine Conference at the Gaylord National Hotel and Convention Center in Washington DC on Thursday, April 14.

8 Apr 2011

Hope4Cancer offers gentle non-invasive therapies for patients with brain tumor

Linda Roberts was puzzled when her favorite food, chocolate ice cream, suddenly did not taste good, and her prized orchids didn't smell nice either. When she began having sudden, severe headaches, she mentioned the changes in taste and smell to her doctor. After several tests, Roberts was diagnosed with a glioblastoma multiforme, the most aggressive form of brain tumor.

8 Apr 2011

Opinions: Support antibiotic R&D; foreign aid budget cuts

"The framework for antibiotic discovery, development and approval is broken," Matthew Cooper of the University of Queensland and David Shales, former vice president at Wyeth Pharmaceuticals, write in a Nature comment, calling for "a sustained effort from government and industry to develop new drugs quickly."

8 Apr 2011

CoMeD urges UN to ban mercury use in pharmaceuticals

While the United Nations actively questions the use of a vaccine preservative that contains the known neurotoxin mercury, the Coalition for Mercury-Free Drugs, a Maryland-based, non-profit organization, is urging the UN to ban it.

7 Apr 2011

Alexion submits Soliris marketing applications to FDA, EMA for aHUS treatment

Alexion Pharmaceuticals, Inc. announced today that the company has submitted marketing applications to the U.S. Food and Drug Administration and the European Medicines Agency for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome.

7 Apr 2011

Pitt, UPCI researchers' cancer studies presented at AACR meeting

How do certain multiple myeloma treatment drugs cause complications? How does the immune system become dysfunctional due to cancer? How safe is a vaccine that could prevent development of precancerous colon polyps? Those are among the many questions that will be answered by researchers from the University of Pittsburgh Cancer Institute and the University of Pittsburgh School of Medicine during the American Association for Cancer Research 102nd Annual Meeting 2011, April 2 to 6, in Orlando, Fla.

7 Apr 2011

U.S., Canada research institutions to participate in NCI's Cancer Immunotherapy Trials Network

Research institutions at 27 sites in the U.S. and Canada have been selected to participate in the Cancer Immunotherapy Trials Network, a new initiative in immunotherapy funded by the National Cancer Institute and headquartered at Fred Hutchinson Cancer Research Center.

7 Apr 2011

World Health Day 2011 highlights problem of antimicrobial resistance

On the eve of World Health Day 2011, Inter Press Service examines the growing global challenge of antibimicrobial resistance.

7 Apr 2011

Top 10 global pharmaceutical company, Medicago sign deal to develop non-influenza vaccine

Medicago Inc., a biotechnology company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced that it has entered into a research collaboration agreement for the development of a non-influenza vaccine candidate with a top 10 global pharmaceutical company.

7 Apr 2011

Nuron Biotech announces acquisition of Wyeth's HibTITER vaccine assets

Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has acquired assets relating to the vaccine HibTITER from Wyeth LLC, a wholly owned subsidiary of Pfizer Inc, for the U.S. and many other markets, including Japan and Korea. Financial terms of the sale were not disclosed.

7 Apr 2011

Roswell Park Cancer Institute selected to be part of Cancer Immunotherapy Trials Network

Roswell Park Cancer Institute (RPCI) is one of 27 North American research institutions that have been selected to be part of the Cancer Immunotherapy Trials Network (CITN), a new immunotherapy initiative funded by the National Cancer Institute (NCI). Kunle Odunsi, MD, PhD, FRCOG, FACOG, Director of the Center for Immunotherapy and Chair of Gynecologic Oncology at RPCI, will serve as Principal Investigator of the Institute's role in this collaborative investigative effort.

6 Apr 2011

Vaccine News and Research

Latest Vaccine News and Research

Synexus' Chief Medical Officer to discuss vaccine trial challenges at Washington event

Pfizer to support immatics' IMA901 Phase III trial in advanced renal cell carcinoma

Immunization does not increase emergency room visit in children with inherited disorders

Merck announces interim analysis from V710 Phase II/III trial in S. aureus infection

Gilenya can reduce risk of disability progression in patients with RRMS

IDSA, U.S. health officials describe ways to respond to global threat of antimicrobial resistance

Scientists identify novel mechanism to control cancer spread

New dengue test receives FDA marketing clearance

Key regulator of fat cell development may provide a target for obesity and diabetes drugs

GeoVax Labs to update its HIV/AIDS vaccine status at World Vaccine Conference

Hope4Cancer offers gentle non-invasive therapies for patients with brain tumor

Opinions: Support antibiotic R&D; foreign aid budget cuts

CoMeD urges UN to ban mercury use in pharmaceuticals

Alexion submits Soliris marketing applications to FDA, EMA for aHUS treatment

Pitt, UPCI researchers' cancer studies presented at AACR meeting

U.S., Canada research institutions to participate in NCI's Cancer Immunotherapy Trials Network

World Health Day 2011 highlights problem of antimicrobial resistance

Top 10 global pharmaceutical company, Medicago sign deal to develop non-influenza vaccine

Nuron Biotech announces acquisition of Wyeth's HibTITER vaccine assets

Roswell Park Cancer Institute selected to be part of Cancer Immunotherapy Trials Network

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Vaccine News and Research

Latest Vaccine News and Research

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Newsletters you may be interested in